Gion, M., García-Mosquera, J., Pérez-García, J., Peg, V., Ruiz-Borrego, M., Stradella, A., . . . Cortés, J. (2024). Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Citación estilo ChicagoGion, M., et al. Correlation between Trophoblast Cell-surface Antigen-2 (Trop-2) Expression and Pathological Complete Response in Patients With HER2-positive Early Breast Cancer Treated With Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. 2024.
Cita MLAGion, M., et al. Correlation between Trophoblast Cell-surface Antigen-2 (Trop-2) Expression and Pathological Complete Response in Patients With HER2-positive Early Breast Cancer Treated With Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. 2024.